Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data on RA drug peficitinib: safety check in 3,000 patients

NCT ID NCT03971253

Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and effective peficitinib is for people with rheumatoid arthritis (RA) in everyday medical practice. About 3,000 patients who were starting peficitinib for the first time took part. Researchers tracked side effects and measured disease activity using standard scores like DAS28. The goal was to understand how the drug works outside of controlled clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,000 people

The number who actually took part.

Started

Sep 2019

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time. Exclusion Criteria: * Not applicable.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis (RA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis (RA)

Contacts and locations

Locations

  • Site JP00001

    Hokkaido, Japan

  • Site JP00002

    Aomori, Japan

  • Site JP00003

    Numakunai, Japan

  • Site JP00004

    Miyagi, Japan

  • Site JP00005

    Akita, Japan

  • Site JP00006

    Yamagata, Japan

  • Site JP00007

    Fukushima, Japan

  • Site JP00008

    Ibaraki, Japan

  • Site JP00009

    Tochigi, Japan

  • Site JP00010

    Gunma, Japan

  • Site JP00011

    Saitama, Japan

  • Site JP00012

    Chiba, Japan

  • Site JP00013

    Tokyo, Japan

  • Site JP00014

    Kanagawa, Japan

  • Site JP00015

    Niigata, Japan

  • Site JP00016

    Toyama, Japan

  • Site JP00017

    Ishikawa, Japan

  • Site JP00018

    Fukui, Japan

  • Site JP00019

    Yamanashi, Japan

  • Site JP00020

    Nagano, Japan

  • Site JP00021

    Gifu, Japan

  • Site JP00022

    Shizuoka, Japan

  • Site JP00023

    Aichi, Japan

  • Site JP00024

    Mie, Japan

  • Site JP00025

    Shiga, Japan

  • Site JP00026

    Kyoto, Japan

  • Site JP00027

    Osaka, Japan

  • Site JP00028

    Hyōgo, Japan

  • Site JP00029

    Nara, Japan

  • Site JP00030

    Wakayama, Japan

  • Site JP00031

    Tottori, Japan

  • Site JP00032

    Shimane, Japan

  • Site JP00033

    Okayama, Japan

  • Site JP00034

    Hiroshima, Japan

  • Site JP00035

    Yamaguchi, Japan

  • Site JP00036

    Tokushima, Japan

  • Site JP00037

    Kagawa, Japan

  • Site JP00038

    Ehime, Japan

  • Site JP00039

    Kochi, Japan

  • Site JP00040

    Fukuoka, Japan

  • Site JP00041

    Saga, Japan

  • Site JP00042

    Nagasaki, Japan

  • Site JP00043

    Kumamoto, Japan

  • Site JP00044

    Ōita, Japan

  • Site JP00045

    Miyazaki, Japan

  • Site JP00046

    Kagoshima, Japan

  • Site JP00047

    Okinawa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.